NEUPNeuphoria Therapeutics Inc.
This is the year Neuphoria Therapeutics has to prove it’s not just a vaporware story. The next catalyst — the Phase 2 CNS efficacy data release on 2026-10-20 — is the first real test of whether the company can deliver on its clinical promise. If the data is positive, the stock could rally to $4.83, with a bull probability of 55%, and the path to Phase 3 initiation and beyond opens. If not, the bear fallback drops to $2.46, and the company’s credibility takes a hit. This is the moment where the narrative shifts from “potential” to “proven.”
The Read
3% after Q1 2026 results met expectations but cash runway concerns dominated, then rose 2%.
The schedule
- Tue20Oct
Release of Phase 2 clinical trial results for CNS indications
- Sun25Oct
Potential regulatory approval for Phase 3 trials or initiation of Phase 3 trials
- Fri12Feb
Quarterly earnings report with guidance on cash runway and clinical progress
- Fri14May
- Fri14May
Past
- Tue15Sep
Potential equity raise to fund clinical trials or expansion
- Fri14Aug
Actual outcome: Bull · $3.95 at outcome
NEUP reported an EPS actual of -0.0933, matching the estimate, indicating no earnings beat or miss. However, the stock rose 2.1% from the event date to the outcome date, likely due to positive sentiment around the company's R&D pipeline and cash runway. The market may have interpreted the stable earnings and focus on long-term strategic initiatives as a sign of stability and growth potential, driving the rally.
Q2 2026 earnings focusing on cash runway and R&D pipeline spend.
- Fri15May
Actual outcome: Bear · $4.29 at outcome
Neuphoria Therapeutics reported Q1 2026 EPS of $0.41, exactly in line with consensus estimates. Despite meeting headline expectations, the stock declined 9.3% toward the bear floor by the outcome date. This negative price action indicates that the company's cash runway update and R&D spend details failed to alleviate investor concerns regarding accelerating cash burn and the potential need for a near-term capital raise.
Q1 2026 results for Neuphoria Therapeutics, with focus on R&D spend, non-cash items behind recent P&L volatility, and an updated cash runway disclosure at a share price of $4.96. A clean quarter with disciplined burn and a clear runway message could lift the stock toward $5.60, while any indication of accelerating cash burn or the need for a near-term raise could push it down toward $5.60 by the outcome date.
